Form 4: Pacira BioSciences Director Abraham Ceesay Granted Significant Equity Awards

Pacira BioSciences, Inc. Director Abraham Ceesay was granted 6,163 restricted stock units and options to purchase 11,279 shares of common stock, aligning his interests with shareholders.

Summary

• Abraham Ceesay, a Director of Pacira BioSciences, Inc. (PCRX), acquired 6,163 shares of common stock through Restricted Stock Units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 and represent the contingent right to receive one share of common stock per unit.
• The RSUs are scheduled to vest on June 11, 2026, provided Mr. Ceesay remains in continuous service with the issuer.
• Additionally, Mr. Ceesay was granted stock options to acquire 11,279 shares of common stock on June 11, 2025.
• These stock options have an exercise price of $24.34 and were granted at a price of $0.
• The stock options will vest and become exercisable on June 11, 2026, contingent on Mr. Ceesay's continuous service.
• Following these transactions, Mr. Ceesay beneficially owns 11,393 shares of common stock directly and 11,279 stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates an increase in insider ownership and alignment of a director's interests with the company's long-term performance through equity grants. There are no negative transactions (e.g., sales) reported.

Positives

• The acquisition of restricted stock units and stock options by a director indicates alignment of management interests with shareholder value.
• The grants incentivize long-term commitment and performance from the director.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the reporting person remaining in continuous service with the issuer through the vesting date (June 11, 2026). If service ceases, the unvested awards may be forfeited.

Future Outlook

The future outlook for the reporting person's equity holdings is tied to the vesting schedule of the granted RSUs and stock options, which are set to vest on June 11, 2026, contingent on continuous service.

Industry Context

This filing is a standard disclosure of insider equity compensation, common across publicly traded companies in all industries, including the biotechnology and pharmaceutical sector where Pacira BioSciences operates. It reflects a common practice of aligning director incentives with long-term company performance.

Comparison to Industry Standards

• Equity grants to directors, including restricted stock units and stock options, are a standard component of executive and director compensation packages across the pharmaceutical and biotechnology industries.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar size and market capitalization, though this document does not provide such comparative data.
• The vesting conditions tied to continuous service are also standard practice.

Related Party Transactions

• The grant of 6,163 restricted stock units and 11,279 stock options to Abraham Ceesay, a director of Pacira BioSciences, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the company's stock price increases.
• Employees: While not directly impacting general employees, such compensation structures for leadership can influence overall company culture and incentive programs.

Next Steps

• Vesting of 6,163 restricted stock units on June 11, 2026.
• Vesting and exercisability of 11,279 stock options on June 11, 2026.

Key Dates

Keywords

Pacira BioSciences, PCRX, SEC Form 4, insider transaction, equity grant, restricted stock units, RSUs, stock options, director compensation, insider ownership, executive compensation